EMJ Nephrology 9 [Supplement 4] 2021
CHRONIC kidney disease (CKD) affects approximately 700 million individuals worldwide. Many patients with CKD require haemodialysis, and more than two-thirds of these patients have CKD-associated pruritus (CKD-aP). CKD-aP can be bothersome for many patients and drastically affect quality of life, from causing sleep issues to mental health problems. Almost 40% of dialysis patients are at least ‘moderately’ bothered and 19% of patients are at least very much bothered by pruritus.
Chronic Kidney Disease-Associated Pruritus: From Epidemiology to Treatment
Chronic kidney disease-associated pruritus (CKD-aP) occurs in over two-thirds of patients undergoing haemodialysis. The aetiology of CKD-aP may be multifactorial, involving immune system and opioid dysregulation, peripheral neuropathy, and toxin deposition. CKD-aP can be extremely bothersome for some patients, affecting health-related quality of life and sleep, as well as increasing the likelihood of hospitalisation, infections, and death.
EMJ Hematology 9 [Supplement 5] 2021
In this interview, two experts in the field of acute myeloid leukaemia (AML), Jean-Baptiste Micol, University of Paris-Saclay, France, and Thomas Cluzeau, University Hospital of Nice, France, share their views and debate the current landscape of real-world data in AML research and treatment.